other material
confidence high
sentiment positive
materiality 0.65
Network-1's investee ILiAD reports positive Phase 2b results for pertussis vaccine BPZE1
NETWORK-1 TECHNOLOGIES, INC.
- ILiAD's BPZE1 intranasal vaccine met primary endpoint protecting against B. pertussis colonization (p=0.03) in CHAMPION-1 study.
- Vaccine reduced B. pertussis bacterial burden by 98.0% compared with placebo; no serious adverse events.
- Network-1 holds ~6.8% stake in ILiAD from $7M investment.
- ILiAD plans to present full data at World Vaccine Congress on Oct 19, 2023.